Related Experiment Video
Updated: Apr 6, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Oleanolic acid alleviated pressure overload-induced cardiac remodeling
Hai-Han Liao1,2, Nan Zhang3, Hong Feng4
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.
Abstract:
Previous study has demonstrated that oleanolic acid (OA) possessing the anti-inflammatory and anti-oxidant properties blunted high-glucose-induced diabetic cardiomyopathy and ameliorated experimental autoimmune myocarditis in mice. However, little is known about its effects on pressure overload-induced cardiac remodeling. Herein, we investigated the effect of OA on cardiac remodeling and underlying mechanism. Mice, subjected to aortic banding (AB), were randomly assigned into control group and experimental group. OA premixed in diets was administered to mice after 3 days of AB. Echocardiography and catheter-based measurements of hemodynamic parameters were performed after 8 weeks' treatment of OA. Histologic examination and molecular analyses were used to assess cardiac hypertrophy and tissue fibrosis. In addition, the inhibitory effects of OA on H9c2 cardiomyocytes and cardiac primary fibroblast responded to the stimulation of AngII were also investigated. OA ameliorated the systolic and diastolic dysfunction induced by pressure overload evidenced by echocardiography and catheter-based measurements. OA also decreased the mRNA expression of cardiac hypertrophy and fibrosis markers evidenced by RT-PCR. It has been shown in our study that pressure overload activated the phosphorylations of Akt, mTOR, p70s6k, S6, GSK3β, and FoxO3a, and treatment of OA attenuated the phosphorylation of these proteins. In addition, hypertrophy of cardiomyocytes and fibrosis markers induced by AngII was inhibited by OA in vitro. Our findings uncover that OA suppressed AB-induced cardiac hypertrophy, partly by inhibiting the activity of Akt/mTOR pathway, and suggest that treatment of OA may have a benefit on retarding the progress of cardiac remodeling under long terms of pressure overload.
Insights
Oleanolic acid (OA) reduces cardiac hypertrophy and fibrosis in pressure overload models by inhibiting the Akt/mTOR pathway. This suggests OA may benefit patients with cardiac remodeling.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Biology
Background:
- Oleanolic acid (OA) exhibits anti-inflammatory and antioxidant properties.
- Previous studies showed OA's benefits in diabetic cardiomyopathy and autoimmune myocarditis.
- The effect of OA on pressure overload-induced cardiac remodeling is largely unknown.
Purpose of the Study:
- To investigate the effects of OA on cardiac remodeling induced by pressure overload.
- To elucidate the underlying molecular mechanisms of OA's action.
- To assess OA's therapeutic potential in cardiac remodeling.
Main Methods:
- Mice underwent aortic banding (AB) surgery and were treated with OA.
- Echocardiography and hemodynamic measurements assessed cardiac function.
- Histological analysis and RT-PCR evaluated cardiac hypertrophy and fibrosis.
- In vitro studies examined OA's effects on Angiotensin II-stimulated cells.
Main Results:
- OA treatment ameliorated systolic and diastolic dysfunction post-AB.
- OA decreased mRNA expression of cardiac hypertrophy and fibrosis markers.
- Pressure overload-induced phosphorylation of Akt, mTOR, and related proteins was attenuated by OA.
- OA inhibited Angiotensin II-induced cardiomyocyte hypertrophy and fibrosis in vitro.
Conclusions:
- Oleanolic acid suppresses pressure overload-induced cardiac hypertrophy.
- OA acts partly by inhibiting the Akt/mTOR pathway.
- OA may offer therapeutic benefits for long-term pressure overload-induced cardiac remodeling.
More Related Videos
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure II: Pathophysiology
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Angiotensin II Receptor Blockers